BR112013005679A2 - imidazopiridazinas substituídas - Google Patents

imidazopiridazinas substituídas

Info

Publication number
BR112013005679A2
BR112013005679A2 BR112013005679A BR112013005679A BR112013005679A2 BR 112013005679 A2 BR112013005679 A2 BR 112013005679A2 BR 112013005679 A BR112013005679 A BR 112013005679A BR 112013005679 A BR112013005679 A BR 112013005679A BR 112013005679 A2 BR112013005679 A2 BR 112013005679A2
Authority
BR
Brazil
Prior art keywords
compounds
substituted imidazopyridazine
substituted
imidazopyridazine
angiogenesis
Prior art date
Application number
BR112013005679A
Other languages
English (en)
Inventor
Antje Margret Wengner
Dirk Kosemund
Gerhard Siemeister
Marcus Koppitz
Philip Lienau
Rolf Bohlmann
Rolf Jautelat
Ulrich Klar
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of BR112013005679A2 publication Critical patent/BR112013005679A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

imidazopiridazinas substituídas. a presente invenção refere-se a compostos de imidazopiridazina substituída de fórmula geral i: em que r^ 3^, r^ 5^, e a são como definidos nas reivindicações, a métodos de preparo dos referidos compostos, a composições e combinações farmacêuticas compreendendo os referidos compostos e ao uso dos referidos compostos para fabricação de uma composição farmacêutica para o tratamento ou profilaxia de uma doença, em particular de um distúrbio hiper proliferativo e/ou de angiogênese, como um único agente ou em combinação com outros ingredientes ativos.
BR112013005679A 2010-09-10 2011-09-06 imidazopiridazinas substituídas BR112013005679A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10176134 2010-09-10
EP11075022 2011-02-04
EP11170775 2011-06-21
EP11170771 2011-06-21
PCT/EP2011/065368 WO2012032031A1 (en) 2010-09-10 2011-09-06 Substituted imidazopyridazines

Publications (1)

Publication Number Publication Date
BR112013005679A2 true BR112013005679A2 (pt) 2016-05-03

Family

ID=44545741

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013005679A BR112013005679A2 (pt) 2010-09-10 2011-09-06 imidazopiridazinas substituídas

Country Status (38)

Country Link
US (1) US9255100B2 (pt)
EP (1) EP2614063B1 (pt)
JP (1) JP5824050B2 (pt)
KR (1) KR20140032337A (pt)
CN (1) CN103370318B (pt)
AP (1) AP3607A (pt)
AR (1) AR082946A1 (pt)
AU (1) AU2011298844B2 (pt)
BR (1) BR112013005679A2 (pt)
CA (1) CA2810755A1 (pt)
CO (1) CO6720961A2 (pt)
CR (1) CR20130102A (pt)
CU (1) CU24187B1 (pt)
CY (1) CY1117352T1 (pt)
DK (1) DK2614063T3 (pt)
DO (1) DOP2013000054A (pt)
EA (1) EA023420B1 (pt)
EC (1) ECSP13012752A (pt)
ES (1) ES2568220T3 (pt)
HK (1) HK1187623A1 (pt)
HR (1) HRP20160360T1 (pt)
HU (1) HUE028771T2 (pt)
IL (1) IL225058A (pt)
MA (1) MA34516B1 (pt)
ME (1) ME02389B (pt)
MX (1) MX2013002713A (pt)
MY (1) MY185139A (pt)
NZ (1) NZ607904A (pt)
PE (1) PE20131164A1 (pt)
PL (1) PL2614063T3 (pt)
RS (1) RS54661B1 (pt)
SA (1) SA111320735B1 (pt)
SG (1) SG188417A1 (pt)
SI (1) SI2614063T1 (pt)
TW (1) TWI541243B (pt)
UY (1) UY33598A (pt)
WO (1) WO2012032031A1 (pt)
ZA (1) ZA201301756B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ES2671748T3 (es) * 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
ES2605946T3 (es) * 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CA2889919C (en) * 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
EA028800B1 (ru) * 2013-06-13 2017-12-29 Байер Фарма Акциенгезельшафт Комбинация производного имидазопиридазина и митотического средства для лечения рака
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
MX2016010877A (es) * 2014-02-21 2017-05-04 Frost Biologic Inc Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos.
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
TW201613927A (en) * 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2016247476B2 (en) 2015-04-17 2021-12-16 Netherlands Translational Research Center B.V. Prognostic biomarkers for TTK inhibitor chemotherapy
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
BR112018010271A2 (pt) * 2015-12-04 2018-11-27 Exxonmobil Research And Engineering Company material cristalino sintético emm-28, sua preparação e uso
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
AU2017299850B2 (en) 2016-07-18 2021-05-27 University Health Network Solid forms of TTK inhibitor
WO2018189185A1 (en) * 2017-04-11 2018-10-18 Straumann Holding Ag Dental implant
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
EP3924351A4 (en) 2019-02-12 2022-12-21 Sumitomo Pharma Oncology, Inc. FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023113477A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923582B1 (en) 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
EP2287165A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
CA2555263A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
RU2008122967A (ru) * 2005-11-10 2009-12-20 Шеринг Корпорейшн (US) Имидазопиразины в качестве ингибиторов протеинкиназ
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8546394B2 (en) * 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
JP5394404B2 (ja) 2008-02-06 2014-01-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用な置換イミダゾピリダジン類
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CA2760077A1 (en) 2009-04-29 2010-11-04 Marcus Koppitz Substituted imidazoquinoxalines
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2547680B1 (en) 2010-03-18 2015-08-05 Bayer Intellectual Property GmbH Imidazopyrazines
CA2801031A1 (en) 2010-06-01 2011-12-08 Bayer Intellectual Property Gmbh Substituted imidazopyrazines
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
EP2651945A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080234A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140187548A1 (en) 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103403006B (zh) 2010-12-17 2015-11-25 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪
JP2014503521A (ja) 2010-12-17 2014-02-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過増殖性障害の処置におけるｍｐｓ−１およびｔｋｋ阻害剤としての使用のための、イミダゾピラジン類
EP2651946B1 (en) 2010-12-17 2015-05-27 Bayer Intellectual Property GmbH 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Also Published As

Publication number Publication date
CY1117352T1 (el) 2017-04-26
PL2614063T3 (pl) 2016-06-30
TWI541243B (zh) 2016-07-11
ECSP13012752A (es) 2014-01-31
UY33598A (es) 2012-04-30
MY185139A (en) 2021-04-30
AU2011298844A1 (en) 2013-03-28
NZ607904A (en) 2015-02-27
HUE028771T2 (en) 2016-12-28
EA201390339A1 (ru) 2013-09-30
DOP2013000054A (es) 2013-07-31
JP5824050B2 (ja) 2015-11-25
CN103370318A (zh) 2013-10-23
DK2614063T3 (en) 2016-04-18
EP2614063B1 (en) 2016-01-13
CN103370318B (zh) 2016-04-20
KR20140032337A (ko) 2014-03-14
HRP20160360T1 (hr) 2016-05-06
CO6720961A2 (es) 2013-07-31
EP2614063A1 (en) 2013-07-17
IL225058A (en) 2017-03-30
SI2614063T1 (sl) 2016-05-31
PE20131164A1 (es) 2013-10-30
SA111320735B1 (ar) 2015-10-21
EA023420B1 (ru) 2016-06-30
ES2568220T3 (es) 2016-04-28
AP3607A (en) 2016-02-26
MA34516B1 (fr) 2013-09-02
ME02389B (me) 2016-09-20
RS54661B1 (en) 2016-08-31
MX2013002713A (es) 2013-05-22
SG188417A1 (en) 2013-04-30
CU24187B1 (es) 2016-07-29
CU20130033A7 (es) 2013-08-29
ZA201301756B (en) 2016-06-29
TW201211049A (en) 2012-03-16
CA2810755A1 (en) 2012-03-15
WO2012032031A1 (en) 2012-03-15
US9255100B2 (en) 2016-02-09
AU2011298844B2 (en) 2015-02-19
US20130338133A1 (en) 2013-12-19
AP2013006790A0 (en) 2013-04-30
JP2013537174A (ja) 2013-09-30
CR20130102A (es) 2013-04-17
HK1187623A1 (zh) 2014-04-11
AR082946A1 (es) 2013-01-23

Similar Documents

Publication Publication Date Title
BR112013005679A2 (pt) imidazopiridazinas substituídas
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
BR112019008458A2 (pt) 1,2,4-triazolonas 2,4,5-trisubstituídas.
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112019009529A2 (pt) novos derivados de quinolina
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
EP3928800A3 (en) Dry powder composition comprising long-chain rna
BR112015020990A2 (pt) imidazopiridazinas substituídas
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
BR112014014184A2 (pt) triazolopiridinas substituídas e seu uso como inibidores de ttk
PH12016500054A1 (en) Substituted pyrazolo-pyridinamines
PH12017501133A1 (en) Pyrazolopyridinamines
BR112014002958A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
UY35848A (es) Tienopirimidinas
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112018074381A2 (pt) [8-(fenil sulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il] (1h-1,2,3-triazol-4-il)metanonas
EA201591180A1 (ru) Составы ингибитора lfa-1
BR112014027002A2 (pt) composição farmacêutica injetável de dexcetoprofeno e tramadol
TN2014000091A1 (en) Amino-substituted imidazopyridazines
BR112014015193A8 (pt) composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico
BR112015028884A2 (pt) tratamento ou prevenção de depressão utilizando mentol e/ou icilina
BR112015026533A2 (pt) tratamento ou prevenção das desordens do autismo com o uso de mentol, linalol e/ou icilina
TN2013000099A1 (en) Substituted imidazopyridazines

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2530 DE 02-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.